GlassScriptPhysician profile
Daniel Christopher Richard
NPI 1063459667
$4,990.19
in general payments reported to CMS, 2019-2025
25 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $409 · 2021: $811 · 2022: $648 · 2023: $722 · 2024: $680 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,240.45 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $855.48 | 2019-2024 | Airsupra |
| Novo Nordisk INC | $657.23 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $371.82 | 2023-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $357.07 | 2019-2020 | |
| Biotronik Nro, INC. | $182.51 | 2024 | Prospera |
| Abbvie INC. | $175.16 | 2019-2025 | |
| Pfizer INC. | $159.75 | 2019-2022 | |
| Astellas Pharma US INC | $150.01 | 2022-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $140.06 | 2021-2025 | Eterna, Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $135.61 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Mallinckrodt Hospital Products INC. | $127.55 | 2023 | Terlivaz |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $69.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.17 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.42 | 2022-2023 | Jardiance |
| Abiomed | $30.51 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.57 | 2019-2020 | |
| Seqirus USA INC | $25.24 | 2025 | Fluad, Flucelvax |
| Gilead Sciences, INC. | $21.77 | 2019 | |
| Merck Sharp & Dohme LLC | $17.97 | 2019 | |
| Phadia US INC. | $15.44 | 2024 | Immunocap |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
| Sonex Health, INC. | $11.52 | 2023 | Sx-One Microknife |
| Sumitomo Pharma America, INC. | $6.01 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Richard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.